262 related articles for article (PubMed ID: 25338742)
1. Early engineering approaches to improve peptide developability and manufacturability.
Furman JL; Chiu M; Hunter MJ
AAPS J; 2015 Jan; 17(1):111-20. PubMed ID: 25338742
[TBL] [Abstract][Full Text] [Related]
2. Predicting Antibody Developability Profiles Through Early Stage Discovery Screening.
Bailly M; Mieczkowski C; Juan V; Metwally E; Tomazela D; Baker J; Uchida M; Kofman E; Raoufi F; Motlagh S; Yu Y; Park J; Raghava S; Welsh J; Rauscher M; Raghunathan G; Hsieh M; Chen YL; Nguyen HT; Nguyen N; Cipriano D; Fayadat-Dilman L
MAbs; 2020; 12(1):1743053. PubMed ID: 32249670
[TBL] [Abstract][Full Text] [Related]
3. Susceptibility of Antibody CDR Residues to Chemical Modifications Can Be Revealed Prior to Antibody Humanization and Aid in the Lead Selection Process.
Xu A; Kim HS; Estee S; ViaJar S; Galush WJ; Gill A; Hötzel I; Lazar GA; McDonald P; Andersen N; Spiess C
Mol Pharm; 2018 Oct; 15(10):4529-4537. PubMed ID: 30118239
[TBL] [Abstract][Full Text] [Related]
4. Pragmatic mAb lead molecule engineering from a developability perspective.
Chi B; De Oliveira G; Gallagher T; Mitchell L; Knightley L; Gonzalez CC; Russell S; Germaschewski V; Pearce C; Sellick CA
Biotechnol Bioeng; 2021 Oct; 118(10):3733-3743. PubMed ID: 33913507
[TBL] [Abstract][Full Text] [Related]
5. Deamidation and isomerization liability analysis of 131 clinical-stage antibodies.
Lu X; Nobrega RP; Lynaugh H; Jain T; Barlow K; Boland T; Sivasubramanian A; Vásquez M; Xu Y
MAbs; 2019 Jan; 11(1):45-57. PubMed ID: 30526254
[TBL] [Abstract][Full Text] [Related]
6. Unique Impacts of Methionine Oxidation, Tryptophan Oxidation, and Asparagine Deamidation on Antibody Stability and Aggregation.
Alam ME; Slaney TR; Wu L; Das TK; Kar S; Barnett GV; Leone A; Tessier PM
J Pharm Sci; 2020 Jan; 109(1):656-669. PubMed ID: 31678251
[TBL] [Abstract][Full Text] [Related]
7. Physicochemical and formulation developability assessment for therapeutic peptide delivery--a primer.
Bak A; Leung D; Barrett SE; Forster S; Minnihan EC; Leithead AW; Cunningham J; Toussaint N; Crocker LS
AAPS J; 2015 Jan; 17(1):144-55. PubMed ID: 25398427
[TBL] [Abstract][Full Text] [Related]
8. In silico prediction of post-translational modifications in therapeutic antibodies.
Vatsa S
MAbs; 2022; 14(1):2023938. PubMed ID: 35040751
[TBL] [Abstract][Full Text] [Related]
9. Developability studies before initiation of process development: improving manufacturability of monoclonal antibodies.
Yang X; Xu W; Dukleska S; Benchaar S; Mengisen S; Antochshuk V; Cheung J; Mann L; Babadjanova Z; Rowand J; Gunawan R; McCampbell A; Beaumont M; Meininger D; Richardson D; Ambrogelly A
MAbs; 2013; 5(5):787-94. PubMed ID: 23883920
[TBL] [Abstract][Full Text] [Related]
10. Peptide Developability at the Discovery-to-Development Interface--Current State and Future Opportunities.
Bak A; Dai W
AAPS J; 2015 Jul; 17(4):777-9. PubMed ID: 25823670
[No Abstract] [Full Text] [Related]
11. Assessing developability early in the discovery process for novel biologics.
Fernández-Quintero ML; Ljungars A; Waibl F; Greiff V; Andersen JT; Gjølberg TT; Jenkins TP; Voldborg BG; Grav LM; Kumar S; Georges G; Kettenberger H; Liedl KR; Tessier PM; McCafferty J; Laustsen AH
MAbs; 2023; 15(1):2171248. PubMed ID: 36823021
[TBL] [Abstract][Full Text] [Related]
12. Current advances in biopharmaceutical informatics: guidelines, impact and challenges in the computational developability assessment of antibody therapeutics.
Khetan R; Curtis R; Deane CM; Hadsund JT; Kar U; Krawczyk K; Kuroda D; Robinson SA; Sormanni P; Tsumoto K; Warwicker J; Martin ACR
MAbs; 2022; 14(1):2020082. PubMed ID: 35104168
[TBL] [Abstract][Full Text] [Related]
13. Boosting antibody developability through rational sequence optimization.
Seeliger D; Schulz P; Litzenburger T; Spitz J; Hoerer S; Blech M; Enenkel B; Studts JM; Garidel P; Karow AR
MAbs; 2015; 7(3):505-15. PubMed ID: 25759214
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of protein engineering and process optimization approaches to enhance antibody drug manufacturability.
Conley GP; Viswanathan M; Hou Y; Rank DL; Lindberg AP; Cramer SM; Ladner RC; Nixon AE; Chen J
Biotechnol Bioeng; 2011 Nov; 108(11):2634-44. PubMed ID: 21618474
[TBL] [Abstract][Full Text] [Related]
15. Predicting deamidation and isomerization sites in therapeutic antibodies using structure-based
Hoffmann D; Bauer J; Kossner M; Henry A; Karow-Zwick AR; Licari G
MAbs; 2024; 16(1):2333436. PubMed ID: 38546837
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic peptides: technological advances driving peptides into development.
Sato AK; Viswanathan M; Kent RB; Wood CR
Curr Opin Biotechnol; 2006 Dec; 17(6):638-42. PubMed ID: 17049837
[TBL] [Abstract][Full Text] [Related]
17. Blueprint for antibody biologics developability.
Mieczkowski C; Zhang X; Lee D; Nguyen K; Lv W; Wang Y; Zhang Y; Way J; Gries JM
MAbs; 2023; 15(1):2185924. PubMed ID: 36880643
[TBL] [Abstract][Full Text] [Related]
18. Developability assessment during the selection of novel therapeutic antibodies.
Jarasch A; Koll H; Regula JT; Bader M; Papadimitriou A; Kettenberger H
J Pharm Sci; 2015 Jun; 104(6):1885-1898. PubMed ID: 25821140
[TBL] [Abstract][Full Text] [Related]
19. Prediction and Reduction of the Aggregation of Monoclonal Antibodies.
van der Kant R; Karow-Zwick AR; Van Durme J; Blech M; Gallardo R; Seeliger D; Aßfalg K; Baatsen P; Compernolle G; Gils A; Studts JM; Schulz P; Garidel P; Schymkowitz J; Rousseau F
J Mol Biol; 2017 Apr; 429(8):1244-1261. PubMed ID: 28322916
[TBL] [Abstract][Full Text] [Related]
20. Susceptibility of protein therapeutics to spontaneous chemical modifications by oxidation, cyclization, and elimination reactions.
Grassi L; Cabrele C
Amino Acids; 2019 Nov; 51(10-12):1409-1431. PubMed ID: 31576455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
